reports
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ADI ANALOG DEVICES INC.
TXN TEXAS INSTRUMENTS INCORPORATED
SCCO SOUTHERN COPPER CORPORATION
POWI POWER INTEGRATIONS INC.
ON ON SEMICONDUCTOR CORPORATION
MOD MODINE MANUFACTURING COMPANY
MCHP MICROCHIP TECHNOLOGY INCORPORATED
LDOS LEIDOS HOLDINGS INC.
JJSF J & J SNACK FOODS CORP.
HSY HERSHEY COMPANY
GPRE GREEN PLAINS INC.
GGG GRACO INC.
GD GENERAL DYNAMICS CORPORATION
FORM FORMFACTOR INC.
FCX FREEPORT-MCMORAN INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ASH ASHLAND GLOBAL HOLDINGS INC.
APOG APOGEE ENTERPRISES INC.
BCPC BALCHEM CORPORATION
TECK.B TECK RESOURCES LIMITED CLASS B
COHU COHU INC.
CRUS CIRRUS LOGIC INC.
ENTG ENTEGRIS INC.
FSLR FIRST SOLAR INC.
LMT LOCKHEED MARTIN CORPORATION
NX QUANEX BUILDING PRODUCTS CORPORATION
WFT.. WEATHERFORD INTERNATIONAL PLC
RDY DR. REDDY'S LABORATORIES LTD. ADS
PI IMPINJ INC.
BHP BHP GROUP
ICHR ICHOR HOLDINGS LTD.
RTP.. RIO TINTO PLC ADS (MEXICO)
AMD ADVANCED MICRO DEVICES INC.
ELD ELDORADO GOLD CORPORATION
CFB CROSSFIRST BANKSHARES
LHX L3HARRIS TECHNOLOGIES INC
HII. HORIZONS CDN INS
RVMD REVOLUTION MEDICINES
CARR CARRIER GLOBAL CORP.
UTZ UTZ BRANDS INC (A)
OTIS OTIS WORLDWIDE CORPORATION
FLNC FLUENCE ENERGY INC
STM STABILUS SE
ELVN IMARA INC
HEI HAWAIIAN ELECTRIC CO INC COM
AMKR 21SHARES MAKER ETP
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim In...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, was published online in the journal ERJ Open Research. The outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of aPAP, resulting in improved lung function, decreased disease burden, restored patient functionality, and reduction of clinical symptoms, and may enable resumption of daily life activities. This case series retrospectively evaluated five aPAP pati...
Savara Announces Participation in Upcoming Healthcare Investor Confere...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending two upcoming healthcare investor conferences and participating in fireside chats at each. Guggenheim SMID Cap Biotech Conference, February 5-6, 2025 Fireside Chat: February 5th, 10:00am ET/7:00am PT Oppenheimer 35th Annual Healthcare Life Sciences Conference, February 11-12, 2025 Fireside Chat: February 11th, 8:00am ET/5:00am PT The live webcasts and subsequent replays will be av...
Mustang Bio Announces Reverse Stock Split
Mustang Bio Announces Reverse Stock Split WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that it will effect a 1-for-50 reverse stock split of its issued and outstanding common stock. Mustang expects its common stock to begin trading on a split-adjusted basis on The Nasdaq Stock Market as of the commencement of trading on January 16, 2025. T...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to five new employees. On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 100,000 shares of the Company’s common stock. These equity...
Savara Initiates Rolling Submission of a Biologics License Application...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs. MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with aPAP. As a result, the Company is allowed to submit individual modules of the BLA as they are completed rather th...
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthca...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference. Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara Location: Westin St. Francis, San Francisco, Elizabethan C Room The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at and will...
- Jonathan Moreland
RMAX RE/MAX HOLDINGS INC.
PSEC PROSPECT CAPITAL CORPORATION
PPSI PIONEER POWER SOLUTIONS
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ANGI ANGI INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MBIN MERCHANTS BANCORP
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
BDSX BIODESIX
CSU CAPITAL SENIOR LIVING
MODV MODIVCARE INC
GRNT GRANIT SKOPKE
UAN CVR PARTNERS LP
INBX INHIBRX
OSCR INC.
WOLF OSCAR HEALTH
CLVT WOLFSPEED INC
ZETA CLARIVATE PLC
RWAY ZETA GLOBAL HLDGS CORP
CGBD RUNWAY GROWTH FINANCE CORP
NXGL TCG BDC
BIGZ INC.
DOUG NEXGEL INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
EP DOUGLAS ELLIMAN INC
MIO WK KELLOGG CO
MDRR EMPIRE PETROLEUM CORP
BNTC PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
FGF BENITEC BIOPHARMA INC
EATON VANCE INSD CALIF MUN BD FD
FG FINANCIAL GROUP
INC.
Leidos Holdings Inc: 1 director
A director at Leidos Holdings Inc bought 2,000 shares at 161.130USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- . (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees. On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of the Company’s common stock. These equity ...
Savara Announces Encore Presentation of Results from the Phase 3 IMPAL...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society (BTS) Winter Meeting, taking place November 27-29, 2024, in London, England. BTS Platform Presentation Details Title: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from IMPALA-...
Savara Inc: 1 director
A director at Savara Inc bought 100,000 shares at 2.876USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Jonathan Moreland
PPSI PIONEER POWER SOLUTIONS
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SMRT SMARTSPACE SOFTWARE
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
REYN REYNOLDS CONSUMER PRODUCTS INC.
UAN CVR PARTNERS LP
OSCR OSCAR HEALTH
ZETA ZETA GLOBAL HLDGS CORP
BGS B&G FOODS
EP INC.
MIO EMPIRE PETROLEUM CORP
MDRR PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
ACMR EATON VANCE INSD CALIF MUN BD FD
A.C. MOORE ARTS & CRAFTS
INC.
Savara Announces Participation in Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats. Jefferies London Healthcare Conference, November 19-21, 2024 Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024 Fireside Chat: December 3rd, 8:30am ET/5:30am PT The live webcasts and subsequent replays will be available...
Cannae Holdings, Inc. Announces Third Quarter 2024 Financial Results
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) has released its third quarter 2024 financial results by posting them to its website. Please visit the Cannae website at to view the third quarter 2024 financial results, which are included in its Letter to Shareholders. Conference Call As previously announced, Cannae will host a conference call, today, November 12, 2024 at 5:00pm (Eastern Time), to discuss its third quarter 2024 results. The conference call can be accessed by dialing 1-844-826-3035 (domestic) or 1-412-317-5195 (international) and ...
Mustang Bio Receives Positive Listing Determination from Nasdaq
Mustang Bio Receives Positive Listing Determination from Nasdaq WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, including the $...
Savara Reports Third Quarter 2024 Financial Results and Provides Busin...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2024 and provided a business update. “After a productive pre-BLA meeting with the FDA, we are working diligently to initiate a rolling submission for MOLBREEVI by the end of this year, with plans to complete the BLA submission by the end of 1Q 2025—thus enabling a potential approval in the U.S. by the end of 2025, if priority review is granted,” said Matt Pauls, Chair and CEO, Sa...
Cannae Holdings, Inc. Announces Quarterly Cash Dividend of $0.12
LAS VEGAS--(BUSINESS WIRE)-- Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. The dividend will be payable December 31, 2024, to shareholders of record as of December 17, 2024. About Cannae Holdings, Inc. We primarily acquire interests in operating companies and are actively engaged in managing and operating a core group of those companies. We believe that our long-term ownership and active involvement in the management and operations of companies helps maximize the value of t...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HS...
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1 oncolytic virus) and MB-101 (IL13Rα2‐targeted CAR-T cell therapy) to optimize clinical results WORCESTER, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating tod...
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Co...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: ) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara's website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation sol...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.